A. Esmaeilzadeh, K. Hadiloo, M. Jabbari, R. Elahi, Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors. Life Sci. 122381 (2023)

S. Tahmasebi, R. Elahi, A. Esmaeilzadeh, Solid tumors challenges and new insights of CAR T cell engineering. Stem Cell Rev Rep 15, 619–636 (2019)

Article  PubMed  Google Scholar 

K. Pan, H. Farrukh, C. Vcsr, H. Xu, P. C-x, Z. Zhu, CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J. Exp. Clin. Cancer Res. 41(1), 119 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

T. Xin, L. Cheng, C. Zhou, Y. Zhao, Z. Hu, X. Wu, In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front. Oncol. 12, 809754 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

X. Zhang, J. Wu, L. Qiao, L. Chen, C. Chen, H. Zhang, et al., Case report: cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease. Front. Oncol. 13, 1008828 (2023)

Article  PubMed  PubMed Central  Google Scholar 

T. Jo, S. Yoshihara, Y. Okuyama, K. Fujii, T. Henzan, K. Kahata, et al., Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan. Br. J. Haematol. 202(2), 256–266 (2023)

Article  CAS  PubMed  Google Scholar 

K. Hadiloo, S. Taremi, M. Heidari, A. Esmaeilzadeh, The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomarker Res. 11(1), 103 (2023)

Article  Google Scholar 

K. Hadiloo, S. Tahmasebi, A. Esmaeilzadeh, CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Can. Cell Inter. 23(1), 86 (2023)

Article  CAS  Google Scholar 

K.M. Cappell, J.N. Kochenderfer, A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18(11), 715–727 (2021)

Article  CAS  PubMed  Google Scholar 

M. Chmielewski, H. Abken, TRUCKS, The fourth-generation CAR T cells: current developments and clinical translation. Adv. Cell Gene Ther. 33 (2020)

R. Elahi, E. Khosh, S. Tahmasebi, A. Esmaeilzadeh, Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front. Immunol. 9, 1717 (2018)

Article  PubMed  PubMed Central  Google Scholar 

J. Tomasik, M. Jasiński, G.W. Basak, Next generations of CAR-T cells-new therapeutic opportunities in hematology? Front. Immunol. 13, 1034707 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

X. Gu, D. He, C. Li, H. Wang, G. Yang, Development of inducible CD19-CAR T cells with a Tet-on system for controlled activity and enhanced clinical safety. Int. J. Mol. Sci. 19(11), 3455 (2018)

Article  PubMed  PubMed Central  Google Scholar 

R. Elahi, A.H. Heidary, K. Hadiloo, A. Esmaeilzadeh, Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects. Stem Cell Rev. Rep. 17, 2081–2106 (2021)

Article  PubMed  PubMed Central  Google Scholar 

K. Hadiloo, S. Taremi, S.H. Safa, S. Amidifar, A. Esmaeilzadeh, The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs. Pharmacol. Res. 107158 (2024)

S.Z.F. Kiaei, A. Nouralishahi, M. Ghasemirad, M. Barkhordar, S. Ghaffari, H. Kheradjoo, et al., Advances in natural killer cell therapies for breast cancer. Immunol. Cell Biol. 101(8), 705–726 (2023)

Article  CAS  PubMed  Google Scholar 

V. Golubovskaya, J. Sienkiewicz, J. Sun, S. Zhang, Y. Huang, H. Zhou, et al., CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo. Int. J. Mol. Sci. 24(17), 13364 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

D. Bollino, T.J. Webb, Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy. Transl. Res. 187, 32–43 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

B.J. Wolf, J.E. Choi, M.A. Exley, Novel approaches to exploiting invariant NKT cells in cancer immunotherapy. Front. Immunol. 9, 384 (2018)

Article  PubMed  PubMed Central  Google Scholar 

Y.-R. Li, Y. Zhou, J. Yu, Y.J. Kim, M. Li, D. Lee, et al., Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat. Biotechnol. 1–16 (2024)

T. Huang, C. Bei, Z. Hu, Y. Li, CAR-macrophage: breaking new ground in cellular immunotherapy. Front Cell Develop. Biol. 12, 1464218 (2024)

Article  Google Scholar 

D. van der Heide, R. Weiskirchen, R. Bansal, Therapeutic targeting of hepatic macrophages for the treatment of liver diseases. Front. Immunol. 10, 2852 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

X. Cui, R. Liu, L. Duan, D. Cao, Q. Zhang, A. Zhang, CAR-T therapy: prospects in targeting cancer stem cells. J. Cell Mol. Med. 25(21), 9891–9904 (2021)

Article  PubMed  PubMed Central  Google Scholar 

M.A. Ceja, M. Khericha, C.M. Harris, C. Puig-Saus, Y.Y. Chen, Cancer focus: CAR-T cell manufacturing: major process parameters and next-generation strategies. J. Exp. Med. 221(2) (2024)

C.C. Pinnix, J.R. Gunther, B.S. Dabaja, P. Strati, P. Fang, M.C. Hawkins, et al., Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 4(13), 2871–2883 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

L. Amini, S.K. Silbert, S.L. Maude, L.J. Nastoupil, C.A. Ramos, R.J. Brentjens, et al., Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19(5), 342–355 (2022)

Article  PubMed  Google Scholar 

G. Dagar, A. Gupta, T. Masoodi, S. Nisar, M. Merhi, S. Hashem, et al., Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J. Transl. Med. 21(1), 449 (2023)

Article  PubMed  PubMed Central  Google Scholar 

M. Wang, J. Munoz, A. Goy, F.L. Locke, C.A. Jacobson, B.T. Hill, et al., KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382(14), 1331–1342 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

C. Perez, I. Gruber, C. Arber, Off-the-shelf allogeneic T cell therapies for cancer: opportunities and challenges using naturally occurring “universal” donor T cells. Front. Immunol. 11, 583716 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

R.M. Martín-Rojas, I. Gómez-Centurión, R. Bailen, M. Bastos, F. Diaz-Crespo, D. Carbonell, et al., Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. Clin. Case Rep. 10(1) (2022)

S.S. Neelapu, S. Tummala, P. Kebriaei, W. Wierda, C. Gutierrez, F.L. Locke, et al., Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15(1), 47–62 (2018)

Article  CAS  PubMed  Google Scholar 

R.M. Sterner, R. Sakemura, M.J. Cox, N. Yang, R.H. Khadka, C.L. Forsman, et al., GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood J. Am. Soc. Hematol. 133(7), 697–709 (2019)

CAS  Google Scholar 

T. Gargett, M.P. Brown, The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front. Pharmacol. 5, 235 (2014)

Article  PubMed  PubMed Central  Google Scholar 

B. Lickefett, L. Chu, V. Ortiz-Maldonado, L. Warmuth, P. Barba, M. Doglio, et al., Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front. Immunol. 14, 1303935 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

L. Short, R.A. Holt, P.R. Cullis, L. Evgin, Direct in vivo CAR T cell engineering. Trends Pharmacol. Sci. (2024)

M. Ayala Ceja, M. Khericha, C.M. Harris, C. Puig-Saus, Y.Y. Chen, CAR-T cell manufacturing: major process parameters and next-generation strategies. J. Exp. Med. 221, 2 (2024)

H. Kim, S. Kim, H. Lim, A.J. Chung, Expanding CAR-T cell immunotherapy horizons through microfluidics. Lab on a Chip. (2024)

C. Laomeephol, S. Areecheewakul, S. Tawinwung, K. Suppipat, P. Chunhacha, N.M. Neves, J.A. Luckanagul, Potential roles of hyaluronic acid in in vivo CAR T cell reprogramming for cancer immunotherapy. Nanoscale. 14(48), 17821–17840 (2022)

Article  CAS